Dual GIP / GLP-1 Receptor Agonist

The most effective
weight loss therapy
available in Nigeria.

0%

Average body weight reduction in clinical trials

Begin Consultation View Clinical Data

Clinical Study Results

0 participants enrolled
72 wk
Duration
Phase III
Trial Stage
NEJM
Published
Clinical Evidence

Head-to-head treatment comparison

Weight reduction outcomes across treatment modalities, measured at 72 weeks in randomized controlled trials.

Tirzepatide 15mg weekly
0%
Semaglutide 2.4mg weekly
0%
Diet & Exercise lifestyle only
0%
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022; 387:205-216. NCT04184622.
Mechanism of Action

Dual-receptor precision therapy

Tirzepatide is the first and only approved dual GIP and GLP-1 receptor agonist, targeting two incretin pathways for superior efficacy.

GIP Receptor Activation

Glucose-dependent insulinotropic polypeptide signaling enhances fat metabolism and reduces lipid storage in adipose tissue.

Pathway 1

GLP-1 Receptor Activation

Glucagon-like peptide-1 signaling reduces appetite, slows gastric emptying, and improves glycaemic control systemically.

Pathway 2

Synergistic Efficacy

Dual-receptor targeting produces 47% greater weight reduction compared to GLP-1-only treatments in clinical trials.

Combined Effect
Weight Loss Projection

Estimate your potential outcome

Based on published clinical literature. Individual results vary depending on adherence, diet, and baseline health.

Current weight kg
50 kg 200 kg
Tirzepatide (Dual-Action)
Semaglutide (15%)
Diet Only (3%)
Patient Outcomes

Documented clinical results

Real outcomes from patients enrolled in our supervised tirzepatide therapy programme across Nigeria.

AO
Adaeze O.
Lagos, Nigeria
-24 kg

"The clinical supervision was exceptional. My doctor monitored every metric, every week. I felt safe throughout and the results exceeded what I thought was possible."

28 weeks
15mg dose
BMI 38 → 29
CE
Chinedu E.
Abuja, Nigeria
-19 kg

"I was sceptical at first, but the data convinced me. After 20 weeks, my HbA1c dropped significantly and I have more energy than I've had in a decade."

24 weeks
10mg dose
BMI 34 → 28
FA
Funke A.
Port Harcourt, Nigeria
-28 kg

"The cold-chain delivery was seamless, even to Port Harcourt. I never missed a dose. The programme is structured, professional, and genuinely life-changing."

32 weeks
15mg dose
BMI 42 → 31
OB
Olumide B.
Ibadan, Nigeria
-22 kg

"Everything was evidence-based. My physician explained the mechanism, titrated my dose carefully, and the weight loss was steady and consistent throughout."

26 weeks
15mg dose
BMI 36 → 29
How It Works

Four steps to clinical care

A streamlined, physician-supervised programme from initial consultation to sustained results.

01

Consult

Free confidential consultation with a licensed physician via WhatsApp. Medical history review and eligibility assessment.

02

Review

Your physician creates a personalised treatment plan with tailored dosing, dietary guidance, and monitoring schedule.

03

Deliver

Cold-chain medication delivered to your door nationwide. Temperature-controlled packaging ensures full potency.

04

Transform

Weekly check-ins, dose titration, and ongoing clinical support. Track your progress with data-driven monitoring.

Frequently Asked

Common questions

Evidence-based answers about tirzepatide therapy, safety, and our clinical programme.

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two incretin hormone pathways simultaneously. Semaglutide (Ozempic, Wegovy) targets only GLP-1. Published clinical literature shows tirzepatide's dual mechanism achieves superior weight reduction, making it highly effective for weight management.
Tirzepatide is administered once weekly via a small subcutaneous injection, typically in the abdomen, thigh, or upper arm. The pre-filled pen uses a very fine needle and most patients report minimal discomfort. Your physician will guide you through self-administration during your initial consultation.
The most common side effects are gastrointestinal: nausea (affecting approximately 20-25% of patients), diarrhea, and decreased appetite. These are typically mild to moderate and diminish significantly after the first 4-8 weeks as your body adjusts. Our gradual dose titration protocol is specifically designed to minimise these effects.
All tirzepatide shipments use pharmaceutical-grade insulated packaging with temperature monitoring strips. We partner with medical logistics providers who maintain 2-8 degrees Celsius throughout transit. Each delivery includes a temperature verification card so you can confirm your medication arrived within safe parameters. We deliver to all 36 states plus FCT.
Tirzepatide is generally appropriate for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidaemia). Eligibility is determined through a comprehensive medical consultation. Certain conditions, including a personal or family history of medullary thyroid carcinoma, may preclude use.
Most patients begin noticing appetite reduction within the first 1-2 weeks. Measurable weight loss typically becomes apparent by week 4-6. The dose is titrated upward gradually over 12-20 weeks to reach the therapeutic dose. Peak efficacy in clinical trials was observed at 72 weeks, with weight loss continuing throughout the treatment period.
Get Started

Begin your consultation

Speak confidentially with a licensed physician about whether tirzepatide therapy is appropriate for you. No obligation, no pressure.

Start on WhatsApp Review the Evidence
Doctor-supervised
Cold-chain delivery
Nationwide Nigeria